TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01631162

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Breath sample in all patients
Description: Breath sample will be collected by a special nylon bag
Study: NCT01272531

Intervention type: DRUG
Intervention: Mood stabilizer treatment
Description: lithium or valproate
Study: NCT02520440

Intervention type: BIOLOGICAL
Intervention: Monitoring of plasmatic levels of Arginine and Glutamine
Description: Measured plasma amino-acids levels
Study: NCT03322683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment with physium device.
Description: This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 45 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy treatmen
Description: The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
Study: NCT00705510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% cyclosporin eye drop
Description: use the medication twice daily for 3 months
Study: NCT00371631

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Insertion of urinary catheters coated with E. coli 83972
Description: All patients in this pilot study were in the treatment arm, which consisted of receiving a urinary catheter that had been pre-coated with a biofilm of E. coli.
Study: NCT03990077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: HL-085 ( Capsule) is one MEK inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is an antineoplastic drug by inhibiting microtubule depolymerization, and attenuating of the effects of bcl-2 and bcl-xL gene expression.
Study: NCT00705510

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.05% cyclosporin eye drop
Description: use the medication twice daily for 3 months
Study: NCT03823768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus
Description: Subjects in this group will take Envarsus daily for 6 months of treatment (goal 24 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
Study: NCT02326844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 673 (talazoparib)
Description: 1 mg by mouth (p.o.) once daily on 28-day cycles until disease progression
Study: NCT03428568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Melanin
Description: Herbal melanin extracted from Nigella sativa seeds
Study: NCT03823768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Immediate release
Description: Subjects in this group will take Tacrolimus immediate release for 6 months of treatment (goal 12 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
Study: NCT00987766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Taken daily by mouth for 6 days every other week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given through a vein in the arm 1 time every other week.
Study: NCT03170219

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: subcutaneous furosemide and sc2wear device
Description: subcutaneous furosemide administered via sc2wear device vs. standard of care
Study: NCT03302039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single shot phenylephrine
Description: A single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed infusion phenylephrine.
Description: Fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Variable infusion phenylephrine.
Description: Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia.
Study: NCT02332863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Back-loaded Needle (Device)
Description: Fiducial marker placement via a traditional 22G back-loaded needle will be performed with multiple endpoints recorded:~* total length of procedure~* how many markers are successfully deployed~* technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preloaded Needle (Device)
Description: Fiducial marker placement via a novel 22G preloaded needle will be performed with multiple endpoints recorded:~* total length of procedure~* how many markers are successfully deployed~* technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation.
Study: NCT02854800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: Participants followed the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: Participants followed the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: Participants followed the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).
Study: NCT01009229

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low and high salt diets
Description: High salt diet: 150mmol/d Low salt diet: 30mmol/d
Study: NCT03407963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: Embolization by microparticles (300-500 microns)
Study: NCT01366781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal ingestion
Description: Meal 511 kcal, meal 743 kcal or meal 1034 kcal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal ingestion
Description: Meal 511 kcal, meal 743 kcal or meal 1034 kcal
Study: NCT02225405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO
Study: NCT00994058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Inhibition (EI) Uterine Pacemaker
Description: An external powered pulse generator, pacemaker for external stimulation of the uterine muscle through the vaginal canal for the therapeutic use of preventing preterm birth.~Patients with preterm contractions (\< 37 weeks gestation) will be monitored for contraction frequency for 20 minutes before, 20 minutes during use of EI and 20 minutes after EI/uterine inhibitor/pacemaker. Device generates a weak electrical current (0-10mA, 0-50 Hz, 0-50mS).
Study: NCT01334242

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Schedule B
Description: Dosing 0.5 hour before breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Schedule C
Description: Dosing immediately before breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Schedule C
Description: Dosing immediately before breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Schedule D
Description: Dosing immediately before lunch
Study: NCT00987766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given through a vein in the arm 1 time every other week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood and tissue collection.
Study: NCT01430195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Narrow-Band UVB Light Treatment
Description: To be administered 3 times/week for 6 months. 72 treatments in total.
Study: NCT02427581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized synthetic long peptide vaccine (Poly ICLC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Study: NCT02319772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4430

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04169607

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic compliance guided individualized positive end-expiratory pressure titration strategy
Description: Basic ventilation: Volume-controlled ventilation (VCV) mode with positive end-expiratory pressure (PEEP) of 8cm H2O after induction of anesthesia，~Recruitment maneuver (RM): Pressure-controlled ventilation (PCV) mode increasing PEEP from 10 to 25cmH2O in step of 5cmH2O per 30s.~PEEP-titration maneuver: ventilation parameters reset as basic ventilation with PEEP still 25cmH2O.Decrease PEEP to 5cmH2O in step of 2cmH2O per 10 respiratory cycles to confirm the highest dynamic lung compliance (Cdy).~After titration: A new RM will be performed and the final PEEP will be the one related to highest Cdy plus 2cm H2O.~Randomized after the second RM. Individualized PEEP arm: maintain individualized PEEP; PEEP8 arm: maintain a fixed PEEP of 8cm H2O.~VCV with other ventilation parameters the same as basic ventilation until extubation .~After discharged from postoperative anesthesia care unit (60 to 90 minutes after extubation): chest CT .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic compliance guided individualized positive end-expiratory pressure titration strategy
Description: Basic ventilation: Volume-controlled ventilation (VCV) mode with positive end-expiratory pressure (PEEP) of 8cm H2O after induction of anesthesia，~Recruitment maneuver (RM): Pressure-controlled ventilation (PCV) mode increasing PEEP from 10 to 25cmH2O in step of 5cmH2O per 30s.~PEEP-titration maneuver: ventilation parameters reset as basic ventilation with PEEP still 25cmH2O.Decrease PEEP to 5cmH2O in step of 2cmH2O per 10 respiratory cycles to confirm the highest dynamic lung compliance (Cdy).~After titration: A new RM will be performed and the final PEEP will be the one related to highest Cdy plus 2cm H2O.~Randomized after the second RM. Individualized PEEP arm: maintain individualized PEEP; PEEP8 arm: maintain a fixed PEEP of 8cm H2O.~VCV with other ventilation parameters the same as basic ventilation until extubation .~After discharged from postoperative anesthesia care unit (60 to 90 minutes after extubation): chest CT .
Study: NCT01812720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03682588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The Functional exercise group performed functional exercise training for 45 minutes twice a week for 14 weeks. The Stretching exercise group performed stretching exercises with the same duration and frequency.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: The Functional exercise group performed functional exercise training for 45 minutes twice a week for 14 weeks. The Stretching exercise group performed stretching exercises with the same duration and frequency.
Study: NCT01895010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupoint electric stimulation
Description: acupoint electric stimulation combined with tropisetron 6mg before TACE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tropisetron
Description: only tropisetron 6mg before TACE
Study: NCT03680677

Intervention type: PROCEDURE
Intervention: Bone Marrow or Peripheral Blood Graft (BMT)
Description: Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.

Intervention type: OTHER
Intervention: Cancer-directed Therapy or Best Supportive Care
Description: Cancer-directed therapy with intensive regimens (7+3, Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care.
Study: NCT04468009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies
Study: NCT03360487

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation in the sublingual region
Description: In the group submitted to sublingual irradiation, disposable plastic wrap will cover the application pen for the purposes of hygiene, and irradiation will take 10 minutes.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation in the sublingual region
Description: In the group submitted to sublingual irradiation, disposable plastic wrap will cover the application pen for the purposes of hygiene, and irradiation will take 10 minutes.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation in the spinal cord
Description: Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
Study: NCT03680677

Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty Assessment
Description: Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty Assessment
Description: Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.
Study: NCT02396407

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined water, sanitation, and hygiene
Description: Water: Free chlorine tablets (Aquatabs; NaDCC) and safe storage vessel to treat and store drinking water.~Sanitation: Free child potties, sani-scoop hoes to remove feces from household, and latrine upgrades to a dual pit latrine for all households in study compounds.~Handwashing: Handwashing stations including soapy water bottles and detergent soap.~Local promoters visit study compounds at least monthly to deliver behavior change messages that focus on (1) treating drinking water for children \< 36 months of age, (2) use of latrines for defecation and the removal of human and animal feces from the compound, and (3) handwashing with soap at critical times around food preparation, defecation, and contact with feces.
Study: NCT03690518

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation
Description: Educational/Counseling/Training : Rehabilitation, , cardiovascular rehabilitation in congenital heart disease
Study: NCT00765479

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein isolate
Description: Given orally
Study: NCT01334242

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Schedule D
Description: Dosing immediately before lunch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Schedule E
Description: Split dose, dosing 1 hour before breakfast and dinner

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Schedule E
Description: Split dose, dosing 1 hour before breakfast and dinner
Study: NCT06666569

Intervention type: DEVICE
Intervention: Use of the test for treatment optimization
Description: Intervention cohort, where the clinician will have information on the test results to support decision making on treatment optimization. The randomization process will be by blocks and weighted to the ADL/IFX ratio of use of these treatments in the usual clinical practice of the participating hospitals, to guarantee a homogeneous distribution of the treatments in the groups at the beginning/end of the follow-up.
Study: NCT03360487

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation in the spinal cord
Description: Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation in the radial artery
Description: Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation in the radial artery
Description: Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
Study: NCT02583009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 0.1%
Description: Topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 0.3%
Description: Topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 1.0%
Description: Topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAC-14028 cream vehicle
Description: Topical application
Study: NCT01428973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Tablets. 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
Study: NCT00195429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study: NCT00765479

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT03428568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Melanin
Description: Herbal melanin extracted from Nigella sativa seeds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Melanin
Description: Herbal melanin extracted from Nigella sativa seeds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: omeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxil
Description: Antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxil
Description: Antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Antibiotic
Study: NCT03428282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VR Box
Description: Distraction will be made during the injection of the drug using this method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tablet Device
Description: Distraction will be made during the injection of the drug using this method

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia
Description: Anesthesia will be obtained by injecting the drug into the oral mucosa before performing the dental treatment.
Study: NCT02243631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Treatment
Study: NCT01265030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: * Loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligrams)~* Starting 24 hours after the initial loading dose, patients will receive a dose of 4 milligrams/meter2 daily; Per Os (PO), by mouth days 2 through 28 (Max dose 4 milligram/day)
Study: NCT01478347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant meningococcal B + OMV NZ
Description: 2 injections 2 months apart
Study: NCT03890224

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: home ventilators
Description: The 3 test treatments are home non-targeted NIV, home targeted NIV and rescue home NIV. COPD patients will be equipped with home ventilators and fitted with either nasal, oronasal or facial masks. All the ventilators used will be CE marked.
Study: NCT02810119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LO2A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo